Proto-Oncogene Proteins p21(ras)

"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.

Descriptor ID	D016283
MeSH Number(s)	D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
Concept/Terms	Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins p21(ras) p21 c-ras c-ras, p21 p21 c ras p21(c-ras) ras Proto-Oncogene Protein p21 ras Proto Oncogene Protein p21 Proto-Oncogene Proteins c-ras Proteins c-ras, Proto-Oncogene Proto Oncogene Proteins c ras c-ras, Proto-Oncogene Proteins Proto-Oncogene Protein ras Proto Oncogene Protein ras ras, Proto-Oncogene Protein ras Proto-Oncogene Product p21 ras Proto Oncogene Product p21 c-ras Proteins c ras Proteins p21(ras) Proto-Oncogene Protein p21(ras) Proto-Oncogene Protein p21(c-N-ras) Proto-Oncogene Protein p21(c-N-ras) p21(N-ras) Proto-Oncogene Protein p21(c-Ha-ras) Proto-Oncogene Protein p21(c-Ha-ras) p21 c-Ha-ras c-Ha-ras, p21 p21 c Ha ras p21(c-Ha-ras) p21 c-H-ras c-H-ras, p21 p21 c H ras c-Ha-ras p21 c Ha ras p21 p21, c-Ha-ras Proto-Oncogene Protein p21(c-Ki-ras) Proto-Oncogene Protein p21(c-Ki-ras) p21 c-Ki-ras c-Ki-ras, p21 p21 c Ki ras p21(c-Ki-ras) p21 c-K-ras c-K-ras, p21 p21 c K ras c-Ki-ras p21 c Ki ras p21 p21, c-Ki-ras

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Acid Anhydride Hydrolases [D08.811.277.040]
GTP Phosphohydrolases [D08.811.277.040.330]
GTP-Binding Proteins [D08.811.277.040.330.300]
Monomeric GTP-Binding Proteins [D08.811.277.040.330.300.400]
ras Proteins [D08.811.277.040.330.300.400.500]
Proto-Oncogene Proteins p21(ras) [D08.811.277.040.330.300.400.500.600]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
Monomeric GTP-Binding Proteins [D12.644.360.525]
ras Proteins [D12.644.360.525.500]
Proto-Oncogene Proteins p21(ras) [D12.644.360.525.500.600]
Proteins [D12.776]
Carrier Proteins [D12.776.157]
GTP-Binding Proteins [D12.776.157.325]
Monomeric GTP-Binding Proteins [D12.776.157.325.515]
ras Proteins [D12.776.157.325.515.500]
Proto-Oncogene Proteins p21(ras) [D12.776.157.325.515.500.600]
Intracellular Signaling Peptides and Proteins [D12.776.476]
Monomeric GTP-Binding Proteins [D12.776.476.525]
ras Proteins [D12.776.476.525.500]
Proto-Oncogene Proteins p21(ras) [D12.776.476.525.500.600]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Proto-Oncogene Proteins p21(ras) [D12.776.624.664.700.200]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins p21(ras)".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.

Bar chart showing 89 publications over 22 distinct years, with a maximum of 10 publications in 2013 and 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1999	1	1	2
2000	0	1	1
2004	0	1	1
2006	2	1	3
2007	1	0	1
2008	1	1	2
2009	1	3	4
2010	0	1	1
2011	2	6	8
2012	1	4	5
2013	2	8	10
2014	1	7	8
2015	8	2	10
2016	2	5	7
2017	3	3	6
2018	4	2	6
2019	2	2	4
2020	1	0	1
2022	1	2	3
2023	0	1	1
2024	3	1	4

Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.

Chao T, Wang ZX, Bowne WB, Yudkoff CJ, Torjani A, Swaminathan V, Kavanagh TR, Roadarmel A, Sholevar CJ, Cannaday S, Krampitz G, Zhan T, Gorgov E, Nevler A, Lavu H, Yeo CJ, Peiper SC, Jiang W. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Arch Pathol Lab Med. 2024 12 01; 148(12):1299-1309.

View in: PubMed
Vitello DJ, Shah D, Wells A, Masnyk L, Cox M, Janczewski LM, Abad J, Dawravoo K, D'Souza A, Suh G, Bayer R, Cristofanilli M, Bentrem D, Liu Y, Zhang H, Santana-Santos L, Jennings LJ, Zhang Q, Chawla A. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy. Ann Surg. 2026 07 01; 284(1):99-107.

View in: PubMed
Francis JH, Silverman RF, Canestraro J, Bossert D, Della Rocca D, Hatzoglou V, Abramson DH, Diamond EL. Histiocytosis of the orbit and its association with KRAS mutations. Blood Adv. 2024 10 08; 8(19):5086-5090.

View in: PubMed
Rodr?guez NA, Patel N, Dariolli R, Ng S, Aleman AG, Gong JQX, Lin HM, Rodr?guez M, Josowitz R, Sol-Church K, Gripp KW, Lin X, Song SC, Fishman GI, Sobie EA, Gelb BD. HRAS-Mutant Cardiomyocyte Model of Multifocal Atrial Tachycardia. Circ Arrhythm Electrophysiol. 2024 04; 17(4):e012022.

View in: PubMed
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081.

View in: PubMed
Wagman LD, Geller DA, Jacobs SA, Petrelli NJ, Allegra CJ, Lipchik C, Pogue-Geile KL, Srinivasan A, Wang Y, O'Connell MJ. NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab. J Surg Oncol. 2022 Dec; 126(8):1494-1503.

View in: PubMed
Gerratana L, Movarek M, Wehbe F, Katam N, Mahalingam D, Donahue J, Shah A, Chae YK, Mulcahy M, Tsarwhas D, Villaflor V, Kalyan A, Hussein M, Patel J, Chandra S, Platanias LC, Gradishar W, Cristofanilli M, Behdad A. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO Precis Oncol. 2022 06; 6:e2100289.

View in: PubMed
Nauheim D, Moskal D, Renslo B, Chadwick M, Jiang W, Yeo CJ, Nevler A, Bowne W, Lavu H. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. J Surg Oncol. 2022 Aug; 126(2):314-321.

View in: PubMed
Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, P?rez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 09 01; 126(17):3972-3981.

View in: PubMed
Zheng R, Shen Q, Mardekian S, Solomides C, Wang ZX, Evans NR. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020 Aug; 160(2):e71-e79.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement